BioMarin's first announcement related to Orapred, the flagship of its new pediatrics focus, wasn't a great one, as the company expects no revenue contribution from the pediatric asthma drug in the second half. Moreover, there's...
CMEA Ventures (San Francisco, Calif.) closed its CMEA Ventures VI fund at $300 million. The fund will invest in four high technology and life science sectors: drug development; pharmaceutical chemistry; high-performance electronics; and outsourcing services....
...Capital Management; Adams Street Partners; Auda Ventures; Commonfund Capital; Diamond Capital Management (agent for the Dow Employees' Pension Plan...
BioMarin's first announcement related to Orapred, the flagship of its new pediatrics focus, wasn't a great one, as the company expects no revenue contribution from the pediatric asthma drug in the second half. Moreover, there's...
CMEA Ventures (San Francisco, Calif.) closed its CMEA Ventures VI fund at $300 million. The fund will invest in four high technology and life science sectors: drug development; pharmaceutical chemistry; high-performance electronics; and outsourcing services....
...Capital Management; Adams Street Partners; Auda Ventures; Commonfund Capital; Diamond Capital Management (agent for the Dow Employees' Pension Plan...